Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Cervantes, A.
Macarulla, T.
Martinelli, E.
Rodriguez-Braun, E.
Ciardiello, F.
Stroh, C.
Nippgen, J.
Baselga, J.
Tabernero, J.
机构：
[1] Univ Valencia, Hosp Clin, Valencia, Spain
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Univ Naples 2, Naples, Italy
[4] Merck KGaA, Darmstadt, Germany
[5] Ciutat Sanitaria Vall dHebron, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4129
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hoehler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Ting, Saskia
    Markus, Peter
    Paul, Andreas
    Schuler, Martin H.
    Trarbach, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) - Primary endpoint analysis of the CEBIFOX trial
    Kasper, S.
    Meiler, J.
    Knipp, H.
    Hoehler, T.
    Reimer, P.
    Steinmetz, T.
    Berger, W.
    Linden, G.
    Ting, S.
    Markus, P.
    Paul, A.
    Dechene, A.
    Kostbade, K.
    Schuler, M.
    Trarbach, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 99 - 100
  • [23] Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI plus cetuximab until disease progression compared to FOLFIRI plus cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer.
    Pinto, Carmine
    Normanno, Nicola
    Orlandi, Armando
    Maiello, Evaristo
    Bilancia, Domenico
    Corsi, Domenico C.
    Tamburini, Emiliano
    Pisconti, Salvatore
    Ferrau, Francesco
    Di Costanzo, Francesco
    Gori, Stefania
    Daniele, Bruno
    Tonini, Giuseppe
    Zaniboni, Alberto
    Soto-Parra, Hector
    Frassinetti, Giovanni Luca
    Iaffaioli, Rosario Vincenz
    Zampino, M. Giulia
    Repetto, Lazzaro
    Barone, Carlo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [24] Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial
    Ciardiello, Fortunato
    Lenz, Heinz-Josef
    Kohne, Claus-Henning
    Heinemann, Volker
    Tejpar, Sabine
    Esser, Regina
    Beier, Frank
    Stroh, Christopher
    Duecker, Klaus
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [25] First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
    Aranda, E.
    Garcia-Alfonso, P.
    Benavides, M.
    Sanchez Ruiz, A.
    Guillen-Ponce, C.
    Safont, M. J.
    Alcaide, J.
    Gomez, A.
    Lopez, R.
    Manzano, J. L.
    Mendez Urena, M.
    Sastre, J.
    Rivera, F.
    Gravalos, C.
    Garcia, T.
    Martin-Valades, J. I.
    Falco, E.
    Navalon, M.
    Gonzalez Flores, E.
    Garcia Tapiador, A. Ma
    Lopez Munoz, A. Ma
    Barrajon, E.
    Reboredo, M.
    Garcia Teijido, P.
    Viudez, A.
    Cardenas, N.
    Diaz-Rubio, E.
    EUROPEAN JOURNAL OF CANCER, 2018, 101 : 263 - 272
  • [26] A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Ciuleanu, T. E.
    Kurteva, G.
    Ocvirk, J.
    Beslija, S.
    Koza, I.
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Scheithauer, W.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] KRAS STATUS AND EFFICACY IN THE CRYSTAL STUDY: 1ST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING FOLFIRI WITH OR WITHOUT CETUXIMAB
    Van Cutsem, Eric
    Lang, Istvan
    D'Haens, Geerts
    Moiseyenko, Vladimir
    Zaluski, Jerzy
    Folprecht, Gunnar
    Tejpar, Sabine
    Nippgen, Johannes
    Stroh, Christopher
    Rougier, Philippe
    ANNALS OF ONCOLOGY, 2008, 19 : 4 - 4
  • [29] RELATIONSHIP OF EFFICACY WITH KRAS STATUS (WILD TYPE [WT] VS MUTANT [MT]) IN PATIENTS WITH IRINOTECAN-REFRACTORY METASTATIC COLORECTAL CANCER (MCRC), TREATED WITH IRINOTECAN AND ESCALATING DOSES OF CETUXIMAB: PRELIMINARY DATA FROM THE EVEREST STUDY
    Tejpar, S.
    Peeters, M.
    Gelderblom, H.
    Humblet, Y.
    Vermorken, J.
    De Hertogh, G.
    Nippgen, J.
    von Heydebreck, A.
    Stroh, C.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 125 - 125
  • [30] Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial
    Folprecht, G.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Zubel, A.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345